Boehringer Pulmonary Fibrosis Drug Gets FDA Breakthrough Status
Boehringer Ingelheim's BI 1015550 is a PDE4B inhibitor with the potential to address both pulmonary fibrosis and inflammation associated with progressive fibrosing interstitial lung diseases.